iX Biopharma (SGX:42C) Ending Cash Position : S$1.52 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Ending Cash Position?

iX Biopharma's Ending Cash Position for the quarter that ended in Dec. 2024 was S$1.52 Mil.

iX Biopharma's quarterly Ending Cash Position declined from Dec. 2023 (S$5.50 Mil) to Jun. 2024 (S$1.15 Mil) but then increased from Jun. 2024 (S$1.15 Mil) to Dec. 2024 (S$1.52 Mil).

iX Biopharma's annual Ending Cash Position declined from Jun. 2022 (S$12.91 Mil) to Jun. 2023 (S$5.93 Mil) and declined from Jun. 2023 (S$5.93 Mil) to Jun. 2024 (S$1.15 Mil).

iX Biopharma Ending Cash Position Historical Data

The historical data trend for iX Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Ending Cash Position Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Ending Cash Position

Get a 7-Day Free Trial

4.47

5.59

12.91

5.93

1.15

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															10.69	5.93	5.50	1.15	1.52

iX Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

iX Biopharma's Ending Cash Position for the fiscal year that ended in Jun. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5.927	+	-4.773
	=	1.15

iX Biopharma's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.154	+	0.366
	=	1.52

iX Biopharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines